Genesis Biopharma to Present at 2011 Biotech Showcase Conference

MANHATTAN BEACH, Calif., Jan. 6, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, announces that CEO Robert Brooke will present a company overview at the Biotech Showcase™ 2011 conference on Wednesday, January 12, 2011, at 9:45 a.m. Pacific time.  The conference is being held at the Parc 55 Wyndham San Francisco – Union Square.

"We look forward to discussing our progress at this conference, which promotes corporate partnering and attracts an audience interested in companies like Genesis," said Mr. Brooke.  "Last year we took steps to advance development of our proprietary anti-CD55 technology in multiple oncology indications and raised nearly $2 million to support its continued development.  

"We have set an aggressive agenda for 2011.  This quarter we plan to announce results from preclinical efficacy studies with our anti-CD55 therapeutic as a monotherapy in multiple cancer types and in combination with currently marketed blockbuster monoclonal antibodies.  These study results will help us determine the best pathway to advance this program toward clinical proof-of-concept, which typically is shown in Phase 2 clinical trials," he added.

More information about the 2011 Biotech Showcase conference is available at http://www.ebdgroup.com/bts/index.php.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies.  For more information on the company, visit www.genesis-biopharma.com.

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Genesis Biopharma, Inc.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.